Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
8
×
investing
8
×
life sciences
national blog main
san francisco blog main
boston top stories
clinical trials
national top stories
san francisco top stories
cancer
deals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
eli lilly
pfizer
president trump
startups
alexion pharmaceuticals
bristol-myers squibb
What
drug
8
×
roundup
bio
cancer
fda
medicines
alzheimer’s
annual
approved
attention
biotech
companies
ipo
plan
prices
research
advantages
affects
ahead
ambien
american
americans
approval
asco
assessed
attendees
bar
blueprint
brings
camp’s
candidate
cash
chicago
city
clinical
combinations
communities
community’s
conference
currently
Language
unset
Current search:
investing
×
drug
×
" boston blog main "
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More